Smoking Cessation > Cost-Effectiveness Author: Kumanan Wilson, MD
Editorial changes - 2009-11-18
Author information and module status
Key Points
Population at Risk
Effectiveness/Harms of Counseling or Intervention on Changing Behavior
Effectiveness/Harms of Behavior Change on Clinical Outcomes
Direct Effectiveness of Intervention/Counseling on Clinical Outcomes
Timeline
Cost-Effectiveness
Patient Education
Referral/Consultation
Guidelines

Tables
References
What's New
Patient Information
Additional Resources
Tools

Quality Measures Quality Measures
Recommendation
Recognize the cost-effectiveness of nicotine replacement therapy and behavioral counseling for smoking cessation and the benefit they provide for a reduction in illness and death associated with smoking.A

Evidence:

  • A meta-analysis of all smoking cessation interventions determined that the average cost per life saved was $1500 for one episode of advice (19). By comparison, the cost-effectiveness of dialysis is $46,322 (1994 dollars) per year of life saved (77).
  • A cost-effectiveness analysis of nicotine patch, based on two meta-analyses, determined that the cost per quality-adjusted life year was between $4390 and $10,943 for men and between $4995 and $6983 for women. These values were sensitive to baseline cessation rates, physician counseling, and discounted rates. The baseline 1-year cessation rates used in this analysis were 2.5% for no intervention, 4% for physician counseling, and 7.9% for physician counseling plus nicotine patch (78).

Comments:

  • A simulation model based upon Swedish population data suggests that including bupropion SR as part of smoking cessation programs is cost-effective, and potentially cost-saving from the societal perspective, compared to the use of nicotine patch or gum (79).

FAQs
Edward Ellerbeck, MD, MPH, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Kumanan Wilson, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.